Drugs / CAR-NK019
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06464861 | Jun 2024 → Jun 2026 overdue | mantle cell lymphoma, primary mediastinal large B-cell lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-NK019 | “All subjects were intravenously administrated with CAR-NK019 at day 0 with a dose of 2x10\^6/kg” NCT06464861 ↗ |
| Modality | Cell therapy | “cord blood-derived CD19 CAR-NK cells” NCT06464861 ↗ |
| Route | Intravenous | “intravenously administrated with CAR-NK019” NCT06464861 ↗ |
| Target | CD19 | “cord blood-derived CD19 CAR-NK cells” NCT06464861 ↗ |